Investor Presentaiton

sanofi Built a leading-edge mRNA platform in just 18 months 898 Execution 7 mRNA Phase 1/2 clinical trials: Flu, RSV, platform, 3 LNPs screened - >600 dedicated employees, of which >250 new recruits Extensive external network of academia, industry and government partnerships Innovation Innovative antigen, mRNA and LNP designs across viral and bacterial targets - Highly competitive LNP selected for improved immunogenicity and better tolerability - Developed high-throughput translational science model with proprietary MIMIC® system to predict clinical outcomes 79 Vaccines Investor Event

View entire presentation